Welcome to our dedicated page for Healixa news (Ticker: EMOR), a resource for investors and traders seeking the latest updates and insights on Healixa stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Healixa's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Healixa's position in the market.
Healixa, Inc. (OTC: EMOR) announced a significant achievement in its thermal deposition water harvesting technology, marking a milestone in its commercialization efforts. The company’s Global AquaDuct® technology can now produce potable water from the atmosphere, demonstrating improved performance in energy efficiency and yield reliability. Healixa has received over $75 million in order indications and plans to showcase its Minimum Viable Product (MVP) to government representatives and NGOs in early 2023. This advancement aims to address the global water scarcity crisis.
Healixa, Inc. (OTC: EMOR) announced the appointment of Richard Alloway II as Executive Vice President for Government Relations, effective January 1, 2023. Mr. Alloway, a former Pennsylvania State Senator with a focus on improving water quality, will lead the company’s public policy efforts to advance its Global AquaDuct™ water initiatives. Healixa aims to enhance clean water access globally. The company believes Mr. Alloway's experience will be instrumental as they approach commercialization of their technology in the coming year.
Healixa, Inc. (OTC: EMOR) has appointed Christopher C. Miller, the former Acting Secretary of Defense, to its advisory board as part of its strategy to prepare for an uplist to a senior exchange and the commercialization of its Global Aquaduct™ atmospheric water harvesting technology. Miller's expertise in government and defense is expected to enhance the company's growth. His military background highlights the technology's potential impact on national security, emphasizing water's rising importance in military operations.
Healixa, Inc. (OTC: EMOR) announced the addition of Brian P. Crotty to its advisory board. Crotty brings over 30 years of technology sector experience, having led significant transformations in various companies. The appointment is part of Healixa's strategy to enhance its advisory board for commercialization efforts. Ian Parker, CEO, emphasized the importance of this move in accelerating growth, particularly as the company prepares to address the global water crisis.
Healixa, Inc. (OTC Pink: EMOR) announces the signing of initial revenue contracts for its AdvocateCare™ subsidiary, focusing on innovative health-tech solutions. CEO Ian Parker highlighted the unique approach to care management, emphasizing proactive holistic care and cost reduction. AdvocateCare™ services include Remote Patient Monitoring, Chronic Care Management, and more. President Diane Koontz noted the successful launch enhances medical providers' profitability and patient care. Healixa aims to transform healthcare delivery through technological advancements, enhancing relationships among patients, providers, and pharmacies.
FAQ
What is the current stock price of Healixa (EMOR)?
What is the market cap of Healixa (EMOR)?
